Perspective Therapeutics, Inc. (NYSE:CATX) Receives Consensus Rating of “Buy” from Brokerages

Shares of Perspective Therapeutics, Inc. (NYSE:CATX) have been assigned a consensus rating of “Buy” from the nine research firms that are covering the firm, Marketbeat.com reports. Eight investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among brokers that have covered the stock in the last year is $21.43.

Several equities analysts recently issued reports on CATX shares. Wedbush started coverage on Perspective Therapeutics in a research report on Tuesday, October 1st. They issued an “outperform” rating and a $25.00 price objective for the company. Oppenheimer reissued an “outperform” rating and set a $22.00 price objective on shares of Perspective Therapeutics in a research report on Friday, October 11th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Perspective Therapeutics in a research report on Monday, September 9th. Bank of America initiated coverage on Perspective Therapeutics in a report on Thursday, July 25th. They set a “buy” rating and a $24.00 target price for the company. Finally, Royal Bank of Canada cut their price target on Perspective Therapeutics from $29.00 to $27.00 and set an “outperform” rating on the stock in a report on Friday, August 16th.

Perspective Therapeutics Price Performance

Shares of CATX stock opened at $12.15 on Friday. Perspective Therapeutics has a 12-month low of $2.20 and a 12-month high of $19.05. The company has a fifty day moving average price of $13.86.

Perspective Therapeutics (NYSE:CATX) last posted its earnings results on Monday, August 12th. The company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.04. The business had revenue of $0.53 million for the quarter. Equities analysts expect that Perspective Therapeutics will post -0.87 EPS for the current fiscal year.

Institutional Trading of Perspective Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the stock. nVerses Capital LLC acquired a new stake in Perspective Therapeutics during the third quarter worth approximately $57,000. Victory Capital Management Inc. acquired a new stake in Perspective Therapeutics during the 2nd quarter worth approximately $117,000. Point72 DIFC Ltd bought a new stake in Perspective Therapeutics in the 2nd quarter valued at $118,000. SG Americas Securities LLC acquired a new position in Perspective Therapeutics in the 3rd quarter valued at $246,000. Finally, The Manufacturers Life Insurance Company acquired a new position in Perspective Therapeutics in the 2nd quarter valued at $188,000. Institutional investors own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.